 SAN FRANCISCO, Nov. 23, 2020 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of 19.00 per share. Including the option exercise, the aggregate gross proceeds to Olema Oncology from the offering were approximately 240.4 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on November 19, 2020, under the ticker symbol OLMA. 